Javascript must be enabled to continue!
The surface‐exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor
View through CrossRef
AbstractTriggering receptor expressed in myeloid (TREM) cells 2, a receptor expressed by myeloid cells, osteoclasts and microglia, is known to play a protective role in bones and brain. Mutations of the receptor (or of its coupling protein, DAP12) sustain in fact a genetic disease affecting the two organs, the polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu‐Hakola disease). So far, specific agonist(s) of TREM2 have not been identified and its (their) transduction mechanisms are largely unknown. Heat shock protein 60 (Hsp60) is a mitochondrial chaperone that can also be harboured at the cell surface. By using constructs including the extracellular domain of TREM2 and the Fc domain of IgGs we have identified Hsp60 as the only TREM2‐binding protein exposed at the surface of neuroblastoma N2A cells and astrocytes, and lacking in U373 astrocytoma. Treatment with Hsp60 was found to stimulate the best known TREM2‐dependent process, phagocytosis, however, only in the microglial N9 cells rich in the receptor. Upon TREM2 down‐regulation, the Hsp60‐induced stimulation of N9 phagocytosis was greatly attenuated. Hsp60 is also released by many cell types, segregated within exosomes or shedding vesicles which might then undergo dissolution. However, the affinity of its binding (Kd = 3.8 μM) might be too low for the soluble chaperone released from the vesicles to the extracellular space to induce a significant activation of TREM2. It might in contrast be appropriate for the binding of TREM2 to Hsp60 exposed at the surface of cells closely interacting with microglia. The ensuing stimulation of phagocytosis could play protective effects on the brain.
Title: The surface‐exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor
Description:
AbstractTriggering receptor expressed in myeloid (TREM) cells 2, a receptor expressed by myeloid cells, osteoclasts and microglia, is known to play a protective role in bones and brain.
Mutations of the receptor (or of its coupling protein, DAP12) sustain in fact a genetic disease affecting the two organs, the polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu‐Hakola disease).
So far, specific agonist(s) of TREM2 have not been identified and its (their) transduction mechanisms are largely unknown.
Heat shock protein 60 (Hsp60) is a mitochondrial chaperone that can also be harboured at the cell surface.
By using constructs including the extracellular domain of TREM2 and the Fc domain of IgGs we have identified Hsp60 as the only TREM2‐binding protein exposed at the surface of neuroblastoma N2A cells and astrocytes, and lacking in U373 astrocytoma.
Treatment with Hsp60 was found to stimulate the best known TREM2‐dependent process, phagocytosis, however, only in the microglial N9 cells rich in the receptor.
Upon TREM2 down‐regulation, the Hsp60‐induced stimulation of N9 phagocytosis was greatly attenuated.
Hsp60 is also released by many cell types, segregated within exosomes or shedding vesicles which might then undergo dissolution.
However, the affinity of its binding (Kd = 3.
8 μM) might be too low for the soluble chaperone released from the vesicles to the extracellular space to induce a significant activation of TREM2.
It might in contrast be appropriate for the binding of TREM2 to Hsp60 exposed at the surface of cells closely interacting with microglia.
The ensuing stimulation of phagocytosis could play protective effects on the brain.
Related Results
TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
Abstract
BACKGROUND: TREM2 is a microglial cell surface receptor, with risk mutations linked to Alzheimer’s disease (AD), including R47H. Binding of ligands to TREM2 trigge...
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
AbstractBackgroundTREM2 is a lipid‐sensing receptor expressed by microglial sub‐populations within neuropathological microenvironments, whose downstream signaling promotes microgli...
Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a surface receptor expressed in macrophages during tissue injury. This receptor plays a role in driving phagocytosis and...
Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells‐2 (TREM2)
Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells‐2 (TREM2)
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor expressed on macrophages, microglial cells, and ...
Anti-60-kDa Heat Shock Protein Antibodies in Fetal Serum: A Biomarker for Unexplained Small for Gestational Age Fetuses
Anti-60-kDa Heat Shock Protein Antibodies in Fetal Serum: A Biomarker for Unexplained Small for Gestational Age Fetuses
<i>Introduction:</i> Small for gestational age (SGA) is an important problem affecting 10% of pregnancies and is associated with significant perinatal morbidity. In abo...
Drug screening targeting TREM2-TYROBP transmembrane binding
Drug screening targeting TREM2-TYROBP transmembrane binding
Abstract
TREM2
encodes a microglial membrane receptor involved in the disease-associated microglia (DAM) phenotype whose activa...
2518. Development And Characterization Of Human Microglial Models To Elucidate HIV Transmission Events And Pathogenesis
2518. Development And Characterization Of Human Microglial Models To Elucidate HIV Transmission Events And Pathogenesis
Abstract
Background
HIV-associated neurocognitive disorders cause significant morbidity and mortality despite the advent of anti...
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Abstract
Alzheimer’s disease (AD) involves a dynamic interaction between neuroinflammation and metabolic dysregulation, where microglia play a central role. These immune ...

